To date, no consensus exists among stakeholders about switching patients between
reference biological products (RPs) and biosimilars, which may have been curbing the …

With the conceptual advance about four decades ago that type 1 diabetes represents an
autoimmune disease, hope arose that immune-based therapies would soon emerge to …

Background Biosimilars have been used for 15 years in the European Union (EU), and have
been shown to reduce costs and increase access to important biological medicines. In spite …

Competition arising from the increasing availability of biosimilar medicines has resulted in
healthcare savings and has provided greater patient access to high cost therapeutics in …

Biosimilar use is limited in some healthcare systems because biosimilars are not well
understood by many healthcare professionals and patients. The knowledge gap is …

Adalimumab, as a TNF inhibitor biologic for the treatment of rheumatoid arthritis, is one of
the top-selling drugs worldwide. As its various patents have gradually expired, experiments …

Highlights•There are different regulatory approaches toward interchanging
biosimilars.•Blinded clinical studies do not reflect switching in clinical practice.•Current data …

In the USA, an interchangeability designation provides biosimilar sponsors with a pathway
for achieving what is standard for small-molecule generics: pharmacy-level auto-substitution …

Objective: To evaluate patient attitudes regarding non-medical switching (NMS) to
biosimilars among patients with autoimmune disease currently receiving a biologic …

Importance Biosimilar drugs are potentially lower-cost versions of biologics that may
improve access to therapy. However, there is a lack of adequate systematic reviews …